Dashboard
Manage Tickers

CHRSCoherus BioSciences, Inc.

Nasdaq coherus.com


$ 2.11 $ -0.11 (-4.93 %)    

Thursday, 09-May-2024 15:59:15 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.33 $ 0.96 (0.22 %)
DIA $ 394.43 $ 3.52 (0.9 %)
SPY $ 520.56 $ 2.98 (0.58 %)
TLT $ 90.69 $ 0.44 (0.49 %)
GLD $ 216.93 $ 3.37 (1.58 %)
$ 2.12
$ 2.22
$ 2.11 x 100
$ 0.00 x 0
$ 2.11 - $ 2.26
$ 1.43 - $ 6.17
2,203,793
na
266.12M
$ 1.22
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-15-2024 12-31-2023 10-K
3 11-06-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 03-06-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-05-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-08-2018 12-31-2017 10-K
27 11-06-2017 09-30-2017 10-Q
28 08-07-2017 06-30-2017 10-Q
29 05-08-2017 03-31-2017 10-Q
30 03-14-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-09-2016 06-30-2016 10-Q
33 05-09-2016 03-31-2016 10-Q
34 02-29-2016 12-31-2015 10-K
35 11-10-2015 09-30-2015 10-Q
36 08-10-2015 06-30-2015 10-Q
37 05-11-2015 03-31-2015 10-Q
38 03-23-2015 12-31-2014 10-K
39 12-15-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

coherus-biosciences-q1-2024-adj-eps-032-misses-024-estimate-sales-77063m-miss-80248m-estimate
Coherus BioSciences Q1 2024 Adj EPS $(0.32...
05/09/2024 21:15:21

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of...

coherus-announces-full-repayment-of-pharmakon-advisors-75m-term-loan
Coherus Announces Full Repayment of Pharma...
05/09/2024 12:46:17

New $38.7 million term loan with a May 2029 maturity $37.5 million royalty monetization financing based on future sales of L...

coherus-to-collaborate-with-cancer-research-institute-on-novel-combination-evaluating-loqtorzi-with-enb-therapeutics-enb-003-for-treatment-of-ovarian-cancer
Coherus To Collaborate With Cancer Researc...
05/08/2024 13:01:49

coherus-presents-preclinical-data-for-chs-1000-a-novel-anti-ilt4-antibody-at-the-2024-aacr-annual-meeting
Coherus Presents Preclinical Data For CHS-...
04/08/2024 12:34:02

– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, le...

hc-wainwright--co-maintains-buy-on-coherus-biosciences-lowers-price-target-to-11
HC Wainwright & Co. Maintains Buy on Coher...
03/20/2024 11:19:10

HC Wainwright & Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price tar...

hc-wainwright--co-reiterates-buy-on-coherus-biosciences-maintains-13-price-target
HC Wainwright & Co. Reiterates Buy on Cohe...
03/14/2024 11:33:18

HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $13 price...

coherus-biosciences-sees-fy24-rd-and-sga-expenses-250m-265m
Coherus BioSciences Sees FY24 R&D And SG&A...
03/13/2024 20:25:39

recap-coherus-biosciences-q4-earnings
Recap: Coherus BioSciences Q4 Earnings
03/13/2024 20:05:06

coherus-biosciences-q4-2023-adj-eps-062-misses-012-estimate-sales-91524m-miss-96400m-estimate
Coherus BioSciences Q4 2023 Adj EPS $(0.62...
03/13/2024 20:03:43

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of...

earnings-scheduled-for-march-13-2024
Earnings Scheduled For March 13, 2024
03/13/2024 10:15:56

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...

earnings-preview-for-coherus-biosciences
Earnings Preview For Coherus BioSciences
03/12/2024 16:00:41

coherus-launches-udenyca-onbody-for-pegfilgrastim-cbqv
Coherus Launches UDENYCA ONBODY For Pegfil...
02/21/2024 13:31:46

– Innovative design enables five-minute pegfilgrastim-cbqv delivery time –– Unique, automatic, retractable needle mechanism eng...

baird-maintains-outperform-on-coherus-biosciences-lowers-price-target-to-9
Baird Maintains Outperform on Coherus BioS...
01/23/2024 20:05:53

Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:CHRS) with a Outperform and lowers the price target from $1...

truist-securities-maintains-buy-on-coherus-biosciences-lowers-price-target-to-8-report-released-on--22-january-2024
Truist Securities Maintains Buy on Coherus...
01/23/2024 12:53:43

Truist Securities analyst Robyn Karnauskas maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price targe...

truist-securities-maintains-buy-on-coherus-biosciences-lowers-price-target-to-8
Truist Securities Maintains Buy on Coherus...
01/23/2024 12:50:32

Truist Securities analyst Robyn Karnauskas maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price targe...

why-commscope-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-mondays-mid-day-session
Why CommScope Shares Are Trading Lower By ...
01/22/2024 18:08:22

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal L...

why-is-cancer-immunotherapy-focused-coherus-biosciences-stock-trading-higher-today
Why Is Cancer Immunotherapy Focused-Coheru...
01/22/2024 14:41:13

Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncolog...

Core News & Articles
Market-Moving News for January 22nd
01/22/2024 13:55:28

SGMT: 94% | Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in B...

why-coherus-biosciences-shares-are-trading-higher-by-22-here-are-20-stocks-moving-premarket
Why Coherus BioSciences Shares Are Trading...
01/22/2024 13:21:24

Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announc...

Core News & Articles
CORRECTION: Coherus To Divest Ophthalmolog...
01/22/2024 12:15:40

Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced it has entered into an agreement to divest its CIMERLI® ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION